Literature DB >> 16302818

Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (Sirtuin) inhibitors.

Antonello Mai1, Silvio Massa, Siva Lavu, Riccardo Pezzi, Silvia Simeoni, Rino Ragno, Francesca R Mariotti, Francesco Chiani, Giorgio Camilloni, David A Sinclair.   

Abstract

In a search for potent inhibitors of class III histone/protein deacetylases (sirtuins), a series of sirtinol analogues have been synthesized and the degree of inhibition was assessed in vitro using recombinant yeast Sir2, human SIRT1, and human SIRT2 and in vivo with a yeast phenotypic assay. Two analogues, namely, 3- and 4-[(2-hydroxy-1-naphthalenylmethylene)amino]-N-(1-phenylethyl)benzamide (i.e., m- and p-sirtinol), were 2- to 10-fold more potent than sirtinol against human SIRT1 and SIRT2 enzymes. In yeast in vivo assay, these two small molecules were as potent as sirtinol. Compounds lacking the 2-hydroxy group at the naphthalene moiety or bearing several modifications at the benzene 2'-position of the aniline portion (carbethoxy, carboxy, and cyano) were 1.3-13 times less potent than sirtinol, whereas the 2'-carboxamido analogue was totally inactive. Both (R)- and (S)-sirtinol had similar inhibitory effects on the yeast and human enzymes, demonstrating no enantioselective inhibitory effect.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16302818     DOI: 10.1021/jm050100l

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  44 in total

1.  Thiosuccinyl peptides as Sirt5-specific inhibitors.

Authors:  Bin He; Jintang Du; Hening Lin
Journal:  J Am Chem Soc       Date:  2012-01-20       Impact factor: 15.419

Review 2.  Sirtuin activators and inhibitors.

Authors:  José M Villalba; Francisco J Alcaín
Journal:  Biofactors       Date:  2012-06-25       Impact factor: 6.113

3.  Sirtuin 1 Regulates Dendritic Cell Activation and Autophagy during Respiratory Syncytial Virus-Induced Immune Responses.

Authors:  Anna B Owczarczyk; Matthew A Schaller; Michelle Reed; Andrew J Rasky; David B Lombard; Nicholas W Lukacs
Journal:  J Immunol       Date:  2015-07-08       Impact factor: 5.422

4.  Peptide switch is essential for Sirt1 deacetylase activity.

Authors:  Hyeog Kang; Jeong-Yong Suh; Young-Sang Jung; Jae-Won Jung; Myung K Kim; Jay H Chung
Journal:  Mol Cell       Date:  2011-10-21       Impact factor: 17.970

5.  Targeting sirtuin-1 in Huntington's disease: rationale and current status.

Authors:  Wenzhen Duan
Journal:  CNS Drugs       Date:  2013-05       Impact factor: 5.749

Review 6.  Sirtuin 1: A Target for Kidney Diseases.

Authors:  Lili Kong; Hao Wu; Wenhua Zhou; Manyu Luo; Yi Tan; Lining Miao; Lu Cai
Journal:  Mol Med       Date:  2015-01-12       Impact factor: 6.354

7.  Metal-binding effects of sirtuin inhibitor sirtinol.

Authors:  Eman A Akam; Ritika Gautam; Elisa Tomat
Journal:  Supramol Chem       Date:  2015-10-15       Impact factor: 1.688

8.  A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington's disease.

Authors:  Marianne R Smith; Adeela Syed; Tamas Lukacsovich; Judy Purcell; Brett A Barbaro; Shane A Worthge; Stephen R Wei; Giuseppe Pollio; Letizia Magnoni; Carla Scali; Luisa Massai; Davide Franceschini; Michela Camarri; Marco Gianfriddo; Enrica Diodato; Russell Thomas; Ozgun Gokce; S J Tabrizi; Andrea Caricasole; Bernard Landwehrmeyer; Liliana Menalled; Carol Murphy; Sylvie Ramboz; Ruth Luthi-Carter; Goran Westerberg; J Lawrence Marsh
Journal:  Hum Mol Genet       Date:  2014-01-16       Impact factor: 6.150

Review 9.  Mammalian sirtuins: biological insights and disease relevance.

Authors:  Marcia C Haigis; David A Sinclair
Journal:  Annu Rev Pathol       Date:  2010       Impact factor: 23.472

10.  Negative regulation of the deacetylase SIRT1 by DBC1.

Authors:  Wenhui Zhao; Jan-Philipp Kruse; Yi Tang; Sung Yun Jung; Jun Qin; Wei Gu
Journal:  Nature       Date:  2008-01-31       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.